Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07225764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CaOx Stone Prevention

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 1, 2027 → Dec 31, 2027
See other at-risk trials from Icahn School of Medicine at Mount Sinai

Record History

  1. Primary completion pushed from Jun 1, 2027 to Dec 31, 2027
    • Study completion pushed from Jun 30, 2027 to Dec 31, 2027
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This single-center randomized controlled trial at Mount Sinai West will enroll 80 patients undergoing percutaneous nephrolithotomy for calcium oxalate stones. Participants will be randomized to receive either empiric therapy or selective therapy guided by 24-hour urine evaluation. The primary outcome is change in calcium oxalate supersaturation at 4 weeks, aiming to determine whether empiric therapy can provide outcomes comparable to selective therapy while simplifying access to prevention.
Trial Details
NCT Number NCT07225764
Lead Sponsor Icahn School of Medicine at Mount Sinai
Conditions
(from sponsor)		 Kidney Stones
Related terms Kidney Calculi, Nephrolithiasis
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov